| Size | Price | Stock | Qty |
|---|---|---|---|
| 1mg |
|
||
| 5mg |
|
||
| Other Sizes |
| Targets |
The specific biological target of Demethylwedelolactone Sulfate has not been extensively characterized. As a sulfated coumestan, it may modulate enzyme activities associated with inflammation and oxidative stress. Sulfation typically reduces the biological activity of the parent aglycone, and the sulfate moiety may facilitate cellular uptake or alter pharmacokinetic properties. The compound may serve as a storage or transport form of the active aglycone.
|
|---|---|
| ln Vitro |
In vitro activity data for Demethylwedelolactone Sulfate are limited. The parent aglycone demethylwedelolactone exhibits anti-inflammatory and hepatoprotective activities, but the sulfated metabolite generally shows reduced potency in these assays. The compound is primarily used as an analytical standard for phytochemical profiling and quality control of Eclipta prostrata extracts, rather than for its own biological activity.
|
| ln Vivo |
In vivo activity data for Demethylwedelolactone Sulfate are not available in the published literature. The compound has not been evaluated in animal models for efficacy in any disease indication. It remains a phytochemical reference standard for analytical and taxonomic purposes and has not been prioritized for pharmacological development.
|
| Enzyme Assay |
For non-cellular analytical assays, Demethylwedelolactone Sulfate is characterized by HPLC with UV detection or LC-MS/MS. It is separated on a C18 column using a gradient of water and acetonitrile containing formic acid. The compound's retention time and mass spectral fragmentation pattern are used for identification and quantification in plant extracts and biological samples.
|
| Cell Assay |
For cell-based assays, Demethylwedelolactone Sulfate would be tested for cytotoxicity and potential anti-inflammatory activity. Cells (e.g., hepatocytes, macrophages) are treated with serial dilutions of the compound for 24-72 hours. Cell viability is assessed by MTT assay. Anti-inflammatory activity is evaluated by measuring LPS-induced NO production and pro-inflammatory cytokine levels (TNF-α, IL-6) by ELISA.
|
| Animal Protocol |
For in vivo experiments, no established protocols exist for Demethylwedelolactone Sulfate. If pursued, the compound would be formulated in a suitable vehicle and administered to rodents via oral gavage or intraperitoneal injection. Endpoints would depend on the hypothesized activity (e.g., anti-inflammatory, hepatoprotective), but given the lack of target identification, in vivo studies are not currently warranted.
|
| References |
| Molecular Formula |
C15H8O10S
|
|---|---|
| Molecular Weight |
380.2830
|
| Exact Mass |
379.983
|
| CAS # |
1318240-80-0
|
| Related CAS # |
Demethylwedelolactone;6468-55-9
|
| PubChem CID |
86764070
|
| Appearance |
Typically exists as solid at room temperature
|
| Source |
Originated from plants: other families
|
| LogP |
1.5
|
| Hydrogen Bond Donor Count |
4
|
| Hydrogen Bond Acceptor Count |
10
|
| Rotatable Bond Count |
2
|
| Heavy Atom Count |
26
|
| Complexity |
674
|
| Defined Atom Stereocenter Count |
0
|
| SMILES |
C1=C(C=C2C(=C1O)C3=C(C4=CC(=C(C=C4O3)O)O)C(=O)O2)OS(=O)(=O)O
|
| InChi Key |
PHQCOGFAQDXAHJ-UHFFFAOYSA-N
|
| InChi Code |
InChI=1S/C15H8O10S/c16-7-3-6-10(4-8(7)17)23-14-12(6)15(19)24-11-2-5(25-26(20,21)22)1-9(18)13(11)14/h1-4,16-18H,(H,20,21,22)
|
| Chemical Name |
(1,8,9-trihydroxy-6-oxo-[1]benzofuro[3,2-c]chromen-3-yl) hydrogen sulfate
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
May dissolve in DMSO (in most cases), if not, try other solvents such as H2O, Ethanol, or DMF with a minute amount of products to avoid loss of samples
|
|---|---|
| Solubility (In Vivo) |
Note: Listed below are some common formulations that may be used to formulate products with low water solubility (e.g. < 1 mg/mL), you may test these formulations using a minute amount of products to avoid loss of samples.
Injection Formulations
Injection Formulation 1: DMSO : Tween 80： Saline = 10 : 5 : 85 (i.e. 100 μL DMSO stock solution → 50 μL Tween 80 → 850 μL Saline)(e.g. IP/IV/IM/SC) *Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH ₂ O to obtain a clear solution. Injection Formulation 2: DMSO : PEG300 ：Tween 80 : Saline = 10 : 40 : 5 : 45 (i.e. 100 μL DMSO → 400 μLPEG300 → 50 μL Tween 80 → 450 μL Saline) Injection Formulation 3: DMSO : Corn oil = 10 : 90 (i.e. 100 μL DMSO → 900 μL Corn oil) Example: Take the Injection Formulation 3 (DMSO : Corn oil = 10 : 90) as an example, if 1 mL of 2.5 mg/mL working solution is to be prepared, you can take 100 μL 25 mg/mL DMSO stock solution and add to 900 μL corn oil, mix well to obtain a clear or suspension solution (2.5 mg/mL, ready for use in animals). View More
Injection Formulation 4: DMSO : 20% SBE-β-CD in saline = 10 : 90 [i.e. 100 μL DMSO → 900 μL (20% SBE-β-CD in saline)] Oral Formulations
Oral Formulation 1: Suspend in 0.5% CMC Na (carboxymethylcellulose sodium) Oral Formulation 2: Suspend in 0.5% Carboxymethyl cellulose Example: Take the Oral Formulation 1 (Suspend in 0.5% CMC Na) as an example, if 100 mL of 2.5 mg/mL working solution is to be prepared, you can first prepare 0.5% CMC Na solution by measuring 0.5 g CMC Na and dissolve it in 100 mL ddH2O to obtain a clear solution; then add 250 mg of the product to 100 mL 0.5% CMC Na solution, to make the suspension solution (2.5 mg/mL, ready for use in animals). View More
Oral Formulation 3: Dissolved in PEG400 (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 2.6296 mL | 13.1482 mL | 26.2964 mL | |
| 5 mM | 0.5259 mL | 2.6296 mL | 5.2593 mL | |
| 10 mM | 0.2630 mL | 1.3148 mL | 2.6296 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
